<?xml version='1.0' encoding='utf-8'?>
<document id="20002087"><sentence text="Inhibition of oral midazolam clearance by boosting doses of ritonavir, and by 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an experimental catalytic mimic of glutathione oxidase."><entity charOffset="19-28" id="DDI-PubMed.20002087.s1.e0" text="midazolam" /><entity charOffset="60-69" id="DDI-PubMed.20002087.s1.e1" text="ritonavir" /><entity charOffset="78-114" id="DDI-PubMed.20002087.s1.e2" text="4,4-dimethyl-benziso-(2H)-selenazine" /><entity charOffset="116-124" id="DDI-PubMed.20002087.s1.e3" text="ALT-2074" /><entity charOffset="162-173" id="DDI-PubMed.20002087.s1.e4" text="glutathione" /><pair ddi="false" e1="DDI-PubMed.20002087.s1.e0" e2="DDI-PubMed.20002087.s1.e0" /><pair ddi="false" e1="DDI-PubMed.20002087.s1.e0" e2="DDI-PubMed.20002087.s1.e1" /><pair ddi="false" e1="DDI-PubMed.20002087.s1.e0" e2="DDI-PubMed.20002087.s1.e2" /><pair ddi="false" e1="DDI-PubMed.20002087.s1.e0" e2="DDI-PubMed.20002087.s1.e3" /><pair ddi="false" e1="DDI-PubMed.20002087.s1.e0" e2="DDI-PubMed.20002087.s1.e4" /><pair ddi="false" e1="DDI-PubMed.20002087.s1.e1" e2="DDI-PubMed.20002087.s1.e1" /><pair ddi="false" e1="DDI-PubMed.20002087.s1.e1" e2="DDI-PubMed.20002087.s1.e2" /><pair ddi="false" e1="DDI-PubMed.20002087.s1.e1" e2="DDI-PubMed.20002087.s1.e3" /><pair ddi="false" e1="DDI-PubMed.20002087.s1.e1" e2="DDI-PubMed.20002087.s1.e4" /><pair ddi="false" e1="DDI-PubMed.20002087.s1.e2" e2="DDI-PubMed.20002087.s1.e2" /><pair ddi="false" e1="DDI-PubMed.20002087.s1.e2" e2="DDI-PubMed.20002087.s1.e3" /><pair ddi="false" e1="DDI-PubMed.20002087.s1.e2" e2="DDI-PubMed.20002087.s1.e4" /><pair ddi="false" e1="DDI-PubMed.20002087.s1.e3" e2="DDI-PubMed.20002087.s1.e3" /><pair ddi="false" e1="DDI-PubMed.20002087.s1.e3" e2="DDI-PubMed.20002087.s1.e4" /></sentence><sentence text="* The viral protease inhibitor ritonavir is known to inhibit clearance of intravenous midazolam"><entity charOffset="31-40" id="DDI-PubMed.20002087.s2.e0" text="ritonavir" /><entity charOffset="86-95" id="DDI-PubMed.20002087.s2.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.20002087.s2.e0" e2="DDI-PubMed.20002087.s2.e0" /><pair ddi="false" e1="DDI-PubMed.20002087.s2.e0" e2="DDI-PubMed.20002087.s2.e1" /></sentence><sentence text=" * ALT-2074, a catalytic mimic of glutathione oxidase, inhibits human cytochrome P450 3A (CYP3A) isoforms in vitro"><entity charOffset="34-45" id="DDI-PubMed.20002087.s3.e0" text="glutathione" /></sentence><sentence text="" /><sentence text="* Short-term administration of low-dose ritonavir increases area under the plasma concentration curve following oral midazolam by a factor of 28"><entity charOffset="40-49" id="DDI-PubMed.20002087.s5.e0" text="ritonavir" /><entity charOffset="117-126" id="DDI-PubMed.20002087.s5.e1" text="midazolam" /><pair ddi="false" e1="DDI-PubMed.20002087.s5.e0" e2="DDI-PubMed.20002087.s5.e0" /><pair ddi="false" e1="DDI-PubMed.20002087.s5.e0" e2="DDI-PubMed.20002087.s5.e1" /></sentence><sentence text=" * Therefore ritonavir is an appropriate positive control inhibitor for clinical drug interaction studies involving CYP3A substrates"><entity charOffset="13-22" id="DDI-PubMed.20002087.s6.e0" text="ritonavir" /></sentence><sentence text=" * Midazolam clearance is weakly inhibited by ALT-2074, consistent with its in vitro profile"><entity charOffset="3-12" id="DDI-PubMed.20002087.s7.e0" text="Midazolam" /></sentence><sentence text="" /><sentence text="We evaluated whether 'boosting' doses of ritonavir can serve as a positive control inhibitor for pharmacokinetic drug-drug interaction studies involving cytochrome P450 3A (CYP3A)"><entity charOffset="41-50" id="DDI-PubMed.20002087.s9.e0" text="ritonavir" /></sentence><sentence text=" The study also determined whether 4,4-dimethyl-benziso-(2H)-selenazine (ALT-2074), an investigational organoselenium compound that acts as a catalytic mimic of glutathione oxidase, inhibits CYP3A metabolism in vivo"><entity charOffset="35-71" id="DDI-PubMed.20002087.s10.e0" text="4,4-dimethyl-benziso-(2H)-selenazine" /><entity charOffset="73-81" id="DDI-PubMed.20002087.s10.e1" text="ALT-2074" /><entity charOffset="103-117" id="DDI-PubMed.20002087.s10.e2" text="organoselenium" /><entity charOffset="161-172" id="DDI-PubMed.20002087.s10.e3" text="glutathione" /><pair ddi="false" e1="DDI-PubMed.20002087.s10.e0" e2="DDI-PubMed.20002087.s10.e0" /><pair ddi="false" e1="DDI-PubMed.20002087.s10.e0" e2="DDI-PubMed.20002087.s10.e1" /><pair ddi="false" e1="DDI-PubMed.20002087.s10.e0" e2="DDI-PubMed.20002087.s10.e2" /><pair ddi="false" e1="DDI-PubMed.20002087.s10.e0" e2="DDI-PubMed.20002087.s10.e3" /><pair ddi="false" e1="DDI-PubMed.20002087.s10.e1" e2="DDI-PubMed.20002087.s10.e1" /><pair ddi="false" e1="DDI-PubMed.20002087.s10.e1" e2="DDI-PubMed.20002087.s10.e2" /><pair ddi="false" e1="DDI-PubMed.20002087.s10.e1" e2="DDI-PubMed.20002087.s10.e3" /><pair ddi="false" e1="DDI-PubMed.20002087.s10.e2" e2="DDI-PubMed.20002087.s10.e2" /><pair ddi="false" e1="DDI-PubMed.20002087.s10.e2" e2="DDI-PubMed.20002087.s10.e3" /></sentence><sentence text="" /><sentence text="Thirteen healthy volunteers received single 3-mg oral doses of midazolam on three occasions: in the control condition, during co-treatment with low-dose ritonavir (three oral doses of 100 mg over 24 h), and during co-treatment with ALT-2074 (three oral doses of 80 mg over 24 h)"><entity charOffset="63-72" id="DDI-PubMed.20002087.s12.e0" text="midazolam" /><entity charOffset="153-162" id="DDI-PubMed.20002087.s12.e1" text="ritonavir" /><pair ddi="false" e1="DDI-PubMed.20002087.s12.e0" e2="DDI-PubMed.20002087.s12.e0" /><pair ddi="false" e1="DDI-PubMed.20002087.s12.e0" e2="DDI-PubMed.20002087.s12.e1" /></sentence><sentence text="" /><sentence text="Ritonavir increased mean (+/-SE) total area under the curve (AUC) for midazolam by a factor of 28"><entity charOffset="0-9" id="DDI-PubMed.20002087.s14.e0" text="Ritonavir" /></sentence><sentence text="4 +/- 4" /><sentence text="2 (P &lt; 0" /><sentence text="001), and reduced oral clearance to 4" /><sentence text="2 +/- 0" /><sentence text="5% of control (P &lt; 0" /><sentence text="001)" /><sentence text=" In contrast, ALT-2074 increased midazolam AUC by 1" /><sentence text="25 +/- 0" /><sentence text="11 (P &lt; 0" /><sentence text="05), and reduced oral clearance to 88 +/- 8% of control" /><sentence text="" /><sentence text="Low-dose ritonavir produces extensive CYP3A inhibition exceeding that of ketoconazole (typically 10- to 15-fold midazolam AUC enhancement), and is a suitable positive control index inhibitor for drug-drug interaction studies"><entity charOffset="9-18" id="DDI-PubMed.20002087.s26.e0" text="ritonavir" /><entity charOffset="73-85" id="DDI-PubMed.20002087.s26.e1" text="ketoconazole" /><pair ddi="false" e1="DDI-PubMed.20002087.s26.e0" e2="DDI-PubMed.20002087.s26.e0" /><pair ddi="false" e1="DDI-PubMed.20002087.s26.e0" e2="DDI-PubMed.20002087.s26.e1" /></sentence><sentence text=" ALT-2074 inhibits CYP3A metabolism to a small degree that is of uncertain clinical importance" /><sentence text="" /></document>